Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stöhlmacher-Williams… - The lancet …, 2013 - thelancet.com
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck

KP Pendleton, JR Grandis - Clinical Medicine Insights …, 2013 - journals.sagepub.com
Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a
devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic …

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

EF Lartigau, E Tresch, J Thariat, P Graff… - Radiotherapy and …, 2013 - Elsevier
Purpose Recurrent head and neck cancer is associated to a poor survival prognosis. A high
toxicity rate is demonstrated when surgery and/or radiotherapy and/or chemotherapy are …

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management …

F Peyrade, D Cupissol, L Geoffrois, F Rolland, C Borel… - Oral oncology, 2013 - Elsevier
OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck …

MCI van Schalkwyk, SE Papa, JP Jeannon… - Human gene therapy …, 2013 - liebertpub.com
Despite several advances, 5-year survival in patients with head and neck squamous cell
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …

[HTML][HTML] Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma

C Xue, Y Huang, PY Huang, QT Yu, JJ Pan, LZ Liu… - Annals of oncology, 2013 - Elsevier
Background We aimed to investigate the efficacy and tolerability of sorafenib combined with
cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal …

Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of …

J Gilbert, JW Lee, A Argiris, M Haigentz Jr… - Head & …, 2013 - Wiley Online Library
Background Constitutive activation of nuclear factor κB (NF‐κB) is associated with poor
prognosis. Irinotecan demonstrates single‐agent activity in head and neck cancer but …

Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck

DM Shin, FR Khuri - Head & neck, 2013 - Wiley Online Library
Most patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) undergo definitive therapy, yet locoregional recurrence and metastasis are …

Multidisciplinary care of the patient with head and neck cancer

V Saloura, A Langerman, S Rudra… - Surgical Oncology …, 2013 - surgonc.theclinics.com
Head and neck cancer (HNC) comprises a heterogeneous group of cancers, which primarily
affect the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx. In 2010, HNC was …

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with …

JP Machiels, MC Kaminsky, U Keller… - Investigational new …, 2013 - Springer
Summary Background This Phase Ib trial assessed the maximum tolerated dose (MTD) and
safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin …